Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 79, Issue 3, 2015, Pages 477-491

  Westerberg, Goran ^a,b   Chiesa, Joseph A ^c   Andersen, Claus A ^a   Diamanti, Daniela ^a   Magnoni, Letizia ^a   Pollio, Giuseppe ^a   Darpo, Borje ^d,e   Zhou, Meijian ^e  

^a Siena Biotech SpA   (Italy)

^b La Crocina Pharmaceutical Consultants DI   (Italy)

^c Covance Clinical Research Ltd ^*  (United Kingdom)

^d DANDERYD HOSPITAL   (Sweden)

^e ICARDIAC TECHNOLOGIES INC   (United States)

Author keywords

concentration effect modelling; first in human; Huntington's disease; SirT1; transcriptional profile

Indexed keywords

PLACEBO; SELISISTAT; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TRANSCRIPTOME;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR FUNCTION; COHORT ANALYSIS; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTIPLE DRUG DOSE; NEUROLOGIC EXAMINATION; NORMAL HUMAN; PHARMACOGENOMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; T WAVE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; DOSE RESPONSE; DRUG EFFECTS; ELECTROCARDIOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; MALE; MIDDLE AGED; SIRTUIN 1; TRANSCRIPTOME; YOUNG ADULT;

EID: 84929998090     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12513     Document Type: Article

References (22)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Walker FO,. Huntington's disease. Lancet 2007; 369: 218-228.
3. Gutekunst C, Norflus F, Hersch S,. The neuropathology of Huntington's disease. In: Huntington's Disease, eds, Bates G, Harper P, Jones L,. New York: Oxford University Press, 2002; 251-275.
4. Bonelli RM, Wenning GK, Kapfhammer HP,. Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 2004; 19: 51-62.
5. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N,. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993.
6. Jeong H, Then F, Melia TJ, Mazzulli JR, Cui L, Savas JN, Voisine C, Paganetti P, Tanese N, Hart AC, Yamamoto A, Krainc D,. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137: 60-72.
7. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, Marsh JL,. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17: 3767-3775.
8. Sadri-Vakili G, Cha JH,. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease. Curr Alzheimer Res 2007; 3: 403-408.
9. Hughes RE,. Polyglutamine disease: acetyltransferases awry. Curr Biol 2002; 12: R141-R143.
10. Butler R, Bates GP,. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006; 7: 784-796.
11. Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A,. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Curr Pharm Biotechnol 2007; 8: 388-400.
12. Napper AD, Hixon J, McDonagh T, Keavey K, Pons JP, Barker J, Yau WT, Amouzegh P, Flegg A, Hamelin E, Thomas RJ, Kates M, Jones S, Navia MA, Saunders JO, DiStefano PS, Curtis R,. Discovery of indoles as potent and selective inhibitors of the deacetylase SirT1. J Med Chem 2005; 48: 8045-8054.
13. Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA, Wei SR, Pollio G, Magnoni L, Scali C, Massai L, Franceschini D, Camarri M, Gianfriddo M, Diodato E, Thomas R, Gokce O, Tabrizi S, Caricasole A, Landwehrmeyer B, Menalled L, Ramboz S, Luthi Carter R, Westerberg G, Marsh JL,. Sirtuin 1 inhibition alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014; 23: 2995-3007.
14. Diamanti D, Lahiri N, Tarditi A, Magnonia M, Fondelli C, Morena E, Malusa F, Pollio G, Diodato E, Tripepi G, Tabrizi SJ, Caricasole A, Mori E,. Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice. J Huntingtons Dis 2013; 2: 185-200.
15. Darpo B, Fossa AA, Couderc JP, Zhou M, Schreyer A, Ticktin M, Zapesochny A,. Improving the precision of QT measurements. Cardiol J 2011; 18: 401-410.
16. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP,. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research 2003; 31: e15.
17. Diamanti D, Mori E, Incarnato D, Malusa F, Fondelli C, Magnoni L, Pollio G,. Whole gene expression profile in blood reveals multiple pathways deregulation in R6/2 mouse model. Biomark Res 2013; 1: 1-14.
18. Siena Biotech SpA. Data on file.
19. Darpo B, Garnett C,. Early QT assessment-how can our confidence in the data be improved? Br J Clin Pharmacol 2012; 76: 642-648.
20. Rohatagi S, Carrothers TJ, Kuwabara-Wagg J, Khariton T,. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs. J Clin Pharmacol 2009; 49: 1284-1296.
21. Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N,. The IQ-CSRC prospective clinical Phase 1 study: 'can early QT assessment using exposure response analysis replace the thorough QT study?'. Ann Noninvasive Electrocardiol 2014; 19: 70-81.
22. ICH harmonized tripartite guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf (last accessed September 2014).